Gilead To Discontinue Phase III ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS
Gilead Sciences, Inc. reported that the Phase III ENHANCE study in higher-risk myelodysplastic syndromes (MDS) has been halted due to futility based on a planned analysis. The safety data in this trial are consistent with the known magrolimab profile and adverse events encountered in this patient population. In individuals with MDS, Gilead suggests stopping magrolimab medication. Magrolimab is a potential first-in-class anti-CD47 immunotherapy with a clinical development program spanning ten potential indications, including ongoing trials in solid tumors and two pivotal ...
